PREVIOTOX
Live / Applied — Third extension granted (statement of use) (as of 23 Dec 2025)
What this means for you
Not registered yet, but its 11 Apr 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97882926
- Mark type
- Stylized text
- Filed
- 11 Apr 2023
- Published for opposition
- 21 May 2024
- Attorney of record
- Jessica L. Rothstein
Goods and services
- Class 005 — Pharmaceuticals: Specimen collection kits for the collection of saliva for use in DNA screening and genetic testing for medical purposes comprised primarily of swabs for medical purposes and also including collection tubes with caps, all with or without stabilizing reagents and with instructions, printed mailing labels and flat pack cardboard mailing boxes; DNA collection kit comprised of DNA collection laboratory swab and swab handle for medical purposes
- Class 010 — Medical apparatus: Anatomic pathology specimen collection kits for use in genetic testing comprised primarily of saliva and blood collection containers for medical purposes sold empty, printed instructions, printed shipping labels and transport packaging; Blood collection kit comprised of blood collection bag, holder for medical sample tubes and vials, and medical sample tubes and vials; Medical diagnostic apparatus for testing and analysis of DNA and genetic samples for medical purposes; Medical specimen collection devices in the nature of empty tubes and vials for the collection of DNA samples for use in medical testing and analysis of genetics; Saliva collection devices for medical purposes
- Class 042 — Scientific and technological services: Scientific research services, namely, DNA screening and genetic testing; medical research services, namely, DNA screening and genetic testing; Medical laboratory testing services; medical and scientific research in the field of genetics and DNA analysis; scientific research and development services relating to predicting toxicity in connection with immunotherapy treatments; research and development for the purpose of determining treatment selection in the field of immune oncology; providing scientific and medical research information in the field of genetics and DNA analysis
- Class 044 — Medical, beauty and agricultural services: Medical and laboratory analysis in connection with the treatment of patients; Processing medical test kits and home sample collection kits; medical testing of saliva and blood; Medical testing for diagnostic or treatment purposes; Genetic testing for medical purposes; medical testing for predicting toxicity in connection with immunotherapy treatments; Medical consultancy services; Medical risk assessment services in the nature of predicting toxicity in connection with immunotherapy treatments
Owner
- Mira DX, Inc., Los Angeles, CA, US
- Mira DX, Inc., Los Angeles, CA, US
Prosecution history
- 24 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Dec 2025 — SOU EXTENSION 3 GRANTED
- 23 Dec 2025 — SOU EXTENSION 3 FILED
- 23 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 24 Jun 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Jun 2025 — SOU EXTENSION 2 GRANTED
- 23 Jun 2025 — SOU EXTENSION 2 FILED
- 23 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 Jan 2025 — SOU EXTENSION 1 GRANTED
- 14 Jan 2025 — SOU EXTENSION 1 FILED
- 13 Jan 2025 — SOU TEAS EXTENSION RECEIVED
- 16 Jul 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 21 May 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 21 May 2024 — PUBLISHED FOR OPPOSITION